| 32.89 0.02 (0.06%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 48.23  |
1-year : | 54.74 |
| Resists | First : | 41.3 |
Second : | 46.86 |
| Pivot price | 36.62 |
|||
| Supports | First : | 32.29 |
Second : | 26.86 |
| MAs | MA(5) : | 33.99 |
MA(20) : | 37.61 |
| MA(100) : | 38.96 |
MA(250) : | 29.96 |
|
| MACD | MACD : | -1.9 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 3.5 |
D(3) : | 5.1 |
| RSI | RSI(14): 29.3 |
|||
| 52-week | High : | 47.84 | Low : | 9.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KOD ] has closed above bottom band by 6.0%. Bollinger Bands are 9.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.15 - 34.38 | 34.38 - 34.58 |
| Low: | 31.75 - 32.03 | 32.03 - 32.28 |
| Close: | 32.46 - 32.9 | 32.9 - 33.3 |
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Thu, 03 Sep 2026
Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts - Yahoo Finance
Tue, 01 Sep 2026
Kodiak Sciences (KOD): Three Phase 3 Readouts In Sight - Will The Data See It Through? - RTTNews
Wed, 26 Aug 2026
What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders - simplywall.st
Fri, 17 Jul 2026
Kodiak Sciences (KOD) awards CEO Perlroth 100,000 stock options - Stock Titan
Thu, 25 Jun 2026
KOD Forecast — Price Target — Prediction for 2027 - TradingView
Tue, 16 Jun 2026
Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage (NASDAQ:KOD) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 102.3 (%) |
| Shares Short | 10,300 (K) |
| Shares Short P.Month | 10,420 (K) |
| EPS | -4.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -60.5 % |
| Return on Equity (ttm) | -368.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -159 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -7.85 |
| PEG Ratio | 0 |
| Price to Book value | 33.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|